Table of Content

Chapter 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
Chapter 4: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE
4.1. Overview
4.1.1. Market Size and Forecast, By Radioisotope
4.2. Technetium 99m
4.3. Fluorine 18
4.4. Iodine I
4.5. Gallium 68
4.6. Others
Chapter 5: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market Size and Forecast, By Application
5.2. Cancer
5.3. Cardiology
5.4. Others
Chapter 6: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE
6.1. Overview
6.1.1. Market Size and Forecast, By Type
6.2. Diagnostic
6.3. Therapeutic
Chapter 7: SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER
7.1. Overview
7.1.1. Market Size and Forecast, By End User
7.2. Hospitals and clinics
7.3. Medical Imaging centers
7.4. Others
Chapter 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
Chapter 9: COMPANY PROFILES
9.1. Samsung Biologics
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.1.7. Key strategic moves and developments
9.2. Daewoong Pharmaceutical
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Chong Kun Dang Pharmaceutical
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Dong-A ST
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. G.HOUSE Pharma
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Yuhan Corporation
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Hanlim Pharm
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Chemo-Sero-Therapeutic Research Institute
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Genexine
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Celltrion Healthcare
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
9.10.7. Key strategic moves and developments



List of Figures

LIST OF FIGURES
FIGURE 01. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF SOUTH KOREA RADIOPHARMACEUTICALS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN SOUTH KOREA RADIOPHARMACEUTICALS MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: SOUTH KOREA RADIOPHARMACEUTICALS MARKET
FIGURE 10. SOUTH KOREA RADIOPHARMACEUTICALS MARKET,BY RADIOISOTOPE, 2022 ($MILLION)
FIGURE 11. SOUTH KOREA RADIOPHARMACEUTICALS MARKET,BY APPLICATION, 2022 ($MILLION)
FIGURE 12. SOUTH KOREA RADIOPHARMACEUTICALS MARKET,BY TYPE, 2022 ($MILLION)
FIGURE 13. SOUTH KOREA RADIOPHARMACEUTICALS MARKET,BY END USER, 2022 ($MILLION)
FIGURE 14. TOP WINNING STRATEGIES, BY YEAR
FIGURE 15. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 16. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 17. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 18. COMPETITIVE DASHBOARD
FIGURE 19. COMPETITIVE HEATMAP: SOUTH KOREA RADIOPHARMACEUTICALS MARKET
FIGURE 20. TOP PLAYER POSITIONING, 2022
FIGURE 21. SAMSUNG BIOLOGICS: NET SALES, 2020-2022*?($MILLION)
FIGURE 22. SAMSUNG BIOLOGICS: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 23. SAMSUNG BIOLOGICS: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 24. DAEWOONG PHARMACEUTICAL: NET SALES, 2020-2022*?($MILLION)
FIGURE 25. DAEWOONG PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 26. DAEWOONG PHARMACEUTICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 27. CHONG KUN DANG PHARMACEUTICAL: NET SALES, 2020-2022*?($MILLION)
FIGURE 28. CHONG KUN DANG PHARMACEUTICAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 29. CHONG KUN DANG PHARMACEUTICAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 30. DONG-A ST: NET SALES, 2020-2022*?($MILLION)
FIGURE 31. DONG-A ST: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 32. DONG-A ST: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 33. G.HOUSE PHARMA: NET SALES, 2020-2022*?($MILLION)
FIGURE 34. G.HOUSE PHARMA: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 35. G.HOUSE PHARMA: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 36. YUHAN CORPORATION: NET SALES, 2020-2022*?($MILLION)
FIGURE 37. YUHAN CORPORATION: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 38. YUHAN CORPORATION: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 39. HANLIM PHARM: NET SALES, 2020-2022*?($MILLION)
FIGURE 40. HANLIM PHARM: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 41. HANLIM PHARM: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 42. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: NET SALES, 2020-2022*?($MILLION)
FIGURE 43. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 44. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 45. GENEXINE: NET SALES, 2020-2022*?($MILLION)
FIGURE 46. GENEXINE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 47. GENEXINE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 48. CELLTRION HEALTHCARE: NET SALES, 2020-2022*?($MILLION)
FIGURE 49. CELLTRION HEALTHCARE: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 50. CELLTRION HEALTHCARE: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

List of Tables

LIST OF TABLES
TABLE 01. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY RADIOISOTOPE, 2022-2032 ($MILLION)
TABLE 02. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 03. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 04. SOUTH KOREA RADIOPHARMACEUTICALS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 05. SAMSUNG BIOLOGICS: KEY EXECUTIVES
TABLE 06. SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
TABLE 07. SAMSUNG BIOLOGICS: OPERATING SEGMENTS
TABLE 08. SAMSUNG BIOLOGICS: PRODUCT PORTFOLIO
TABLE 09. SAMSUNG BIOLOGICS: KEY STRATERGIES
TABLE 10. DAEWOONG PHARMACEUTICAL: KEY EXECUTIVES
TABLE 11. DAEWOONG PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 12. DAEWOONG PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 13. DAEWOONG PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 14. DAEWOONG PHARMACEUTICAL: KEY STRATERGIES
TABLE 15. CHONG KUN DANG PHARMACEUTICAL: KEY EXECUTIVES
TABLE 16. CHONG KUN DANG PHARMACEUTICAL: COMPANY SNAPSHOT
TABLE 17. CHONG KUN DANG PHARMACEUTICAL: OPERATING SEGMENTS
TABLE 18. CHONG KUN DANG PHARMACEUTICAL: PRODUCT PORTFOLIO
TABLE 19. CHONG KUN DANG PHARMACEUTICAL: KEY STRATERGIES
TABLE 20. DONG-A ST: KEY EXECUTIVES
TABLE 21. DONG-A ST: COMPANY SNAPSHOT
TABLE 22. DONG-A ST: OPERATING SEGMENTS
TABLE 23. DONG-A ST: PRODUCT PORTFOLIO
TABLE 24. DONG-A ST: KEY STRATERGIES
TABLE 25. G.HOUSE PHARMA: KEY EXECUTIVES
TABLE 26. G.HOUSE PHARMA: COMPANY SNAPSHOT
TABLE 27. G.HOUSE PHARMA: OPERATING SEGMENTS
TABLE 28. G.HOUSE PHARMA: PRODUCT PORTFOLIO
TABLE 29. G.HOUSE PHARMA: KEY STRATERGIES
TABLE 30. YUHAN CORPORATION: KEY EXECUTIVES
TABLE 31. YUHAN CORPORATION: COMPANY SNAPSHOT
TABLE 32. YUHAN CORPORATION: OPERATING SEGMENTS
TABLE 33. YUHAN CORPORATION: PRODUCT PORTFOLIO
TABLE 34. YUHAN CORPORATION: KEY STRATERGIES
TABLE 35. HANLIM PHARM: KEY EXECUTIVES
TABLE 36. HANLIM PHARM: COMPANY SNAPSHOT
TABLE 37. HANLIM PHARM: OPERATING SEGMENTS
TABLE 38. HANLIM PHARM: PRODUCT PORTFOLIO
TABLE 39. HANLIM PHARM: KEY STRATERGIES
TABLE 40. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: KEY EXECUTIVES
TABLE 41. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: COMPANY SNAPSHOT
TABLE 42. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: OPERATING SEGMENTS
TABLE 43. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: PRODUCT PORTFOLIO
TABLE 44. CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE: KEY STRATERGIES
TABLE 45. GENEXINE: KEY EXECUTIVES
TABLE 46. GENEXINE: COMPANY SNAPSHOT
TABLE 47. GENEXINE: OPERATING SEGMENTS
TABLE 48. GENEXINE: PRODUCT PORTFOLIO
TABLE 49. GENEXINE: KEY STRATERGIES
TABLE 50. CELLTRION HEALTHCARE: KEY EXECUTIVES
TABLE 51. CELLTRION HEALTHCARE: COMPANY SNAPSHOT
TABLE 52. CELLTRION HEALTHCARE: OPERATING SEGMENTS
TABLE 53. CELLTRION HEALTHCARE: PRODUCT PORTFOLIO
TABLE 54. CELLTRION HEALTHCARE: KEY STRATERGIES